AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ET VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of moderate-to-severe vasomotor symptoms (VMS) due to…
1 source
·3h ago